spartalizumab + panobinostat

spartalizumab + panobinostat is an investigational **combination therapy** comprising two agents: - **spartalizumab** is a monoclonal antibody targeting the programmed cell death 1 (PD-1) receptor, functioning as an immune checkpoint inhibitor. It enhances antitumor immune responses by blocking inhibitory signaling mediated by PD-1 on T cells. - **panobinostat** is a pan-histone deacetylase (HDAC) inhibitor that increases acetylation of histone and nonhistone proteins, leading to changes in gene transcription, cell cycle arrest, and apoptosis. Panobinostat is approved for relapsed/refractory multiple myeloma in combination with other agents, but also studied in combination trials for broader antitumor effects[1][2][4][6]. The rationale for combining spartalizumab and panobinostat lies in simultaneous immune activation (via PD-1 blockade) and tumor cell sensitization (via epigenetic modulation), aiming for synergistic antitumor activity. No unique combination product (single brand or code name) is evidenced for spartalizumab + panobinostat; this combination appears investigational and described only in certain experimental or early clinical contexts.

Other names

spartalizumabPDR001PDR-001PDR 001panobinostatLBH589LBH-589LBH 589Farydak